OTHER GROUP COMPANIES
market

Divi's Laboratories Q4FY22 PAT up 78.21% at Rs894.64 crore on sharp pick up in API profitability

Divi's Laboratories Ltd reported 40.84% increase in revenues yoy for the Q4FY22 quarter on consolidated basis at Rs2,518.44 crore

May 23, 2022 8:17 IST | India Infoline News Service
Divi's Laboratories Ltd reported 40.84% increase in revenues yoy for the Q4FY22 quarter on consolidated basis at Rs2,518.44 crore. On a sequential basis, revenues were up for the quarter by 1.01%.

Full year FY22 revenues were up 28.6% at Rs8,960crore. For Q4FY22, Divi witnessed growth across its API and nutraceutical business. Net cash flows from operations were stable.

During the year, the company capitalized assets of Rs935 crore to convert into capitalized assets. Capital WIP (work in progress) amounted to Rs470 crore.

The consolidated net profit for Q4FY22 was up 78.21% at Rs894.64 crore. The net profits was lower by -0.84% on a sequential basis.

The company saw improvement in its EBIT performance across active pharma ingredients (APIs) and also nutraceuticals. 

Net margins were 35.52% in Q4FY22 quarter compared to 28.07% in Q4FY21. NPM was lower compared to 36.19% in Q3FY22.

The company board declared dividend of Rs30 per share or 1500% on par value of Rs2 per share, subject to shareholder approval for fiscal year 2021-22.


Financial highlights for Mar-22 compared yoy and sequentially


Divi's Laboratories
Rs in Crore Mar-22 Mar-21 YOY Dec-21 QOQ
Total Income (Rs cr) ₹ 2,518.44 ₹ 1,788.19 40.84% ₹ 2,493.24 1.01%
Net Profit (Rs cr) ₹ 894.64 ₹ 502.02 78.21% ₹ 902.24 -0.84%
Diluted EPS (Rs) ₹ 33.70 ₹ 18.91 ₹ 33.99
Net Margins 35.52% 28.07% 36.19%

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity